[1]Won Young-Woong,Han Ji-Youn,Lee Geon Kook,Park Seog-Yun,Lim Kun Young,Yoon Kyong-Ah,Yun Tak,Kim Heung Tae,Lee Jin Soo.Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations[J].Journal of clinical pathology,2011,64(11):947-952.

[2]Miaomiao Sheng,Fang Wang,Yueguang Zhao,Shanshan Li,Xiaojie Wang,Tao Shou,Ying Luo,Wenru Tang.Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis[J].European journal of clinical pharmacology,2016,72(1):1-11.

[3]Zhu Yan,Zhang Xiaotong,Li Longyun.Epidermal growth factor receptor tyrosine kinase domain gene mutation and correlated protein expression to gefitinib sensitivity in advanced non- small cell lung cancer[J].Oncology Progress,2006,4(2):147-151,175.

[4]张琳琳,白维君.Clinical effect of icotinib hydrochloride on non-small cell lung cancer combined with EGFR mutation[J].Clinical Journal of Medical Officer,2016(8):841-843.

[5]Youngjoo Lee MD,Geon Kook Lee MD,PhD,Yeon‐Su Lee PhD,Wenji Zhang BS,Jung‐Ah Hwang PhD,Byung‐Ho Nam PhD,Seok Hyun Kim MD,PhD,Joo‐Hang Kim MD,PhD,Tak Yun MD,Ji‐Youn Han MD,PhD,Heung Tae Kim MD,PhD,Jin Soo Lee MD,PhD.Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations[J].Cancer,2014,120(14):2090-2098.

[6]LIU Hai-tao,CHEN Yu-qing.Research progress on epidermal growth factor receptor inhibitors for non-small cell lung cancer therapy[J].International Journal of Respiration,2012,32(8).

[7]Jianfei, Zhu,Ling, Cai,Haoxian, Yang,Yinsheng, Wen,Junye, Wang,Tiehua, Rong,Lanjun, Zhang.Plasma fibrinogen levels are associated with epidermal growth factor receptor gene mutation in Chinese patients with non-small cell lung cancer[J].德国医学,2013(5):203-209.

[8]Akihiko Kawahara,Koichi Azuma,Satoshi Hattori,Kazutaka Nakashima,Yuji Basaki,Jun Akiba,Sinzo Takamori,Hisamichi Aizawa,Takashi Yanagawa,Hiroto Izumi,Kimitoshi Kohno,Suminori Kono,Masayoshi Kage,Michihiko Kuwano,Mayumi Ono.The close correlation between 8-hydroxy-2′-deoxyguanosine and epidermal growth factor receptor activating mutation in non-small cell lung cancer[J].Human pathology,2010,41(7):951-34.

[9]F.N. Zhao,Y.Q. Zhao,L.Z. Han,Y.S. Xie,Y. Liu,Z.X. Ye.Clinicoradiological features associated with epidermal growth factor receptor exon 19 and 21 mutation in lung adenocarcinoma[J].Clinical radiology,2019,74(1):80.e7-80.e17.

[10]崔佳音,;毕力夫,;苏秀兰.Progress of study on epidermal growth factor receptor associated with non-small cell lung cancer[J].China Medical Herald,2014(36):148-152.

[11]Park S J,Kim H T,Lee D H,Kim K P,Kim S-W,Suh C,Lee J S.Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation[J].Lung cancer (Amsterdam, Netherlands),2012,77(3):556-560.

[12]Gridelli C,De Marinis F,Di Maio M,Cortinovis D,Cappuzzo F,Mok T.Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence[J].Lung cancer (Amsterdam, Netherlands),2011,71(3):249-257.

[13]SUN Guang-yuan,ZHAO Xue-wei,LI Bing,XU Zhi-fei,HE Jin,LIU Hui-min.Expression and clinical significance of epidermal growth factor receptor in female non-small cell lung cancer[J].China Oncology,2007,17(5):380-384.

[14]Jantus-Lewintre Eloisa,Sirera Rafael,Cabrera Andrea,Blasco Ana,Caballero Cristina,Iranzo Vega,Rosell Rafael,Camps Carlos.Analysis of the prognostic value of soluble epidermal growth factor receptor plasma concentration in advanced non-small-cell lung cancer patients[J].Clinical lung cancer,2011,12(5):320-327.

[15]Adrian G. Sacher MD,Pasi A. Jänne MD,PhD,Geoffrey R. Oxnard MD.Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non‐small cell lung cancer[J].Cancer,2014,120(15):2289-2298.

[16]ZHAO Xue-wei,SUN Guang-yuan,LI Bing,XU Zhi-fei,HE Jin,LIU Hui-min.Expression and clinical significance of epidermal growth factor receptor in non-small cell lung cancer[J].Journal of Modern Oncology,2007,15(7):919-922.

[17]ZHAO Ya-Li,LI Qi,LI Xiang-Hong,HAN Wei-Dong,HAO Hao-Jie,SI Yi-Ling,WU Zhi-Qiang.Epidermal growth factor receptor mutation in non-small cell lung cancer and breast cancer[J].Hereditas,2007,29(5):547-553.

[18]申洁,李怡蓉,高院,高辉,白璐.Comparison of clinical efficacy of gefitinib and erlotinib treating non-small-cell lung cancer with epider-mal growth factor receptor mutation in either exon 19 or 21[J].Journal of International Oncology,2016(9):659-663.

[19]Swinson D E B,Cox G,O'Byrne K J.Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer[J].British journal of cancer,2004,91(7):1301-1307.

[20]Al-Kuraya Khawla,Siraj Abdul K,Bavi Prashant,Al-Jommah Naif,Ezzat Adnan,Sheikh Salwa,Amr Samir,Al-Dayel Fouad,Simon Ronald,Guido Sauter.High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population[J].Human pathology,2006,37(4):453-457.